Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Scleroderma, Systemic | 16 | 2023 | 446 | 3.750 |
Why?
|
| Lung Diseases, Interstitial | 8 | 2023 | 110 | 2.980 |
Why?
|
| Fibroblasts | 12 | 2023 | 902 | 2.200 |
Why?
|
| Pulmonary Fibrosis | 9 | 2023 | 157 | 1.940 |
Why?
|
| Thrombin | 7 | 2014 | 117 | 1.780 |
Why?
|
| Lung | 11 | 2023 | 849 | 1.350 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 3 | 2019 | 66 | 1.230 |
Why?
|
| Proto-Oncogene Proteins c-met | 3 | 2016 | 33 | 1.200 |
Why?
|
| Hepatocyte Growth Factor | 5 | 2016 | 63 | 1.180 |
Why?
|
| Scleroderma, Localized | 1 | 2023 | 19 | 0.870 |
Why?
|
| Myofibroblasts | 3 | 2023 | 60 | 0.830 |
Why?
|
| Immediate-Early Proteins | 3 | 2008 | 63 | 0.680 |
Why?
|
| Benzimidazoles | 2 | 2011 | 128 | 0.680 |
Why?
|
| Anticoagulants | 2 | 2014 | 356 | 0.670 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2008 | 146 | 0.650 |
Why?
|
| Indoles | 1 | 2019 | 146 | 0.650 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 507 | 0.640 |
Why?
|
| Skin | 3 | 2017 | 451 | 0.630 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 331 | 0.570 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2016 | 28 | 0.550 |
Why?
|
| Signal Transduction | 7 | 2017 | 2689 | 0.540 |
Why?
|
| Smad2 Protein | 1 | 2015 | 42 | 0.530 |
Why?
|
| Adiponectin | 1 | 2015 | 52 | 0.500 |
Why?
|
| Peptides | 1 | 2017 | 455 | 0.490 |
Why?
|
| Cell Lineage | 1 | 2015 | 146 | 0.480 |
Why?
|
| Transcription Factor CHOP | 1 | 2014 | 28 | 0.480 |
Why?
|
| Pulmonary Alveoli | 1 | 2014 | 62 | 0.470 |
Why?
|
| Peptide Fragments | 2 | 2015 | 483 | 0.460 |
Why?
|
| Skin Diseases | 1 | 2015 | 122 | 0.450 |
Why?
|
| Warfarin | 1 | 2014 | 93 | 0.450 |
Why?
|
| Endoplasmic Reticulum | 1 | 2014 | 148 | 0.440 |
Why?
|
| Cells, Cultured | 6 | 2019 | 2673 | 0.410 |
Why?
|
| Epithelial Cells | 1 | 2014 | 431 | 0.400 |
Why?
|
| Fibrosis | 2 | 2017 | 371 | 0.390 |
Why?
|
| beta-Alanine | 1 | 2011 | 20 | 0.390 |
Why?
|
| Antithrombins | 1 | 2011 | 32 | 0.380 |
Why?
|
| Blood Coagulation | 1 | 2010 | 123 | 0.360 |
Why?
|
| Autoimmunity | 1 | 2010 | 118 | 0.350 |
Why?
|
| Apoptosis | 3 | 2014 | 1641 | 0.340 |
Why?
|
| Connective Tissue Growth Factor | 4 | 2009 | 76 | 0.310 |
Why?
|
| Pyridines | 1 | 2009 | 261 | 0.300 |
Why?
|
| Cell Proliferation | 3 | 2013 | 1174 | 0.290 |
Why?
|
| Protein Kinase C | 3 | 2004 | 270 | 0.290 |
Why?
|
| Collagen Type I | 1 | 2007 | 175 | 0.280 |
Why?
|
| Receptor, PAR-1 | 4 | 2014 | 30 | 0.280 |
Why?
|
| Animals | 9 | 2023 | 20880 | 0.280 |
Why?
|
| Actins | 2 | 2009 | 249 | 0.280 |
Why?
|
| Proteomics | 1 | 2008 | 246 | 0.270 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2017 | 126 | 0.270 |
Why?
|
| Cell Movement | 1 | 2008 | 630 | 0.260 |
Why?
|
| Mice, Inbred C57BL | 4 | 2017 | 2791 | 0.260 |
Why?
|
| Cell Survival | 3 | 2015 | 901 | 0.250 |
Why?
|
| Humans | 22 | 2021 | 68549 | 0.250 |
Why?
|
| Hyaluronan Receptors | 2 | 2017 | 142 | 0.240 |
Why?
|
| Caspase 3 | 2 | 2015 | 233 | 0.240 |
Why?
|
| Mice | 6 | 2023 | 8474 | 0.230 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 144 | 0.220 |
Why?
|
| Co-Repressor Proteins | 1 | 2023 | 8 | 0.220 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 15 | 0.220 |
Why?
|
| Cell Culture Techniques | 3 | 2008 | 189 | 0.220 |
Why?
|
| Muscle Contraction | 1 | 2003 | 210 | 0.210 |
Why?
|
| DNA | 1 | 2004 | 597 | 0.200 |
Why?
|
| Dabigatran | 2 | 2011 | 35 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2020 | 2550 | 0.180 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 1 | 2020 | 2 | 0.180 |
Why?
|
| Extracellular Traps | 1 | 2020 | 9 | 0.180 |
Why?
|
| Chemokines, CC | 1 | 2019 | 18 | 0.180 |
Why?
|
| Collagen | 2 | 2015 | 636 | 0.170 |
Why?
|
| Autocrine Communication | 2 | 2017 | 37 | 0.170 |
Why?
|
| Mucin-1 | 1 | 2019 | 35 | 0.170 |
Why?
|
| Phosphorylation | 3 | 2016 | 1200 | 0.170 |
Why?
|
| DNA Methylation | 1 | 2021 | 193 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.170 |
Why?
|
| Neutrophils | 1 | 2020 | 204 | 0.170 |
Why?
|
| Male | 11 | 2020 | 37283 | 0.160 |
Why?
|
| Limit of Detection | 1 | 2017 | 11 | 0.150 |
Why?
|
| Half-Life | 1 | 2017 | 96 | 0.150 |
Why?
|
| Dasatinib | 1 | 2017 | 17 | 0.150 |
Why?
|
| Calibration | 1 | 2017 | 73 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 786 | 0.150 |
Why?
|
| Female | 10 | 2019 | 38021 | 0.140 |
Why?
|
| Antibodies | 1 | 2017 | 241 | 0.140 |
Why?
|
| NADPH Oxidases | 1 | 2017 | 80 | 0.140 |
Why?
|
| Bleomycin | 2 | 2020 | 67 | 0.140 |
Why?
|
| A549 Cells | 1 | 2016 | 50 | 0.140 |
Why?
|
| Down-Regulation | 2 | 2008 | 447 | 0.140 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 1082 | 0.120 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 1446 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1293 | 0.120 |
Why?
|
| HLA-D Antigens | 1 | 2014 | 20 | 0.120 |
Why?
|
| Epigenomics | 1 | 2014 | 29 | 0.120 |
Why?
|
| Protein Kinase C-epsilon | 2 | 2004 | 28 | 0.120 |
Why?
|
| beta Catenin | 1 | 2014 | 73 | 0.120 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 239 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 1030 | 0.110 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2014 | 99 | 0.110 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1753 | 0.110 |
Why?
|
| Hepatic Veins | 1 | 2011 | 13 | 0.100 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 384 | 0.100 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 56 | 0.100 |
Why?
|
| Endothelin-1 | 1 | 2011 | 122 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1034 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2011 | 411 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 1851 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2012 | 326 | 0.080 |
Why?
|
| Autopsy | 1 | 2008 | 56 | 0.080 |
Why?
|
| Vimentin | 1 | 2008 | 47 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2011 | 301 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2324 | 0.080 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2007 | 74 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 82 | 0.070 |
Why?
|
| Transfection | 1 | 2008 | 782 | 0.070 |
Why?
|
| Wound Healing | 1 | 2008 | 260 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 247 | 0.070 |
Why?
|
| Disease Progression | 2 | 2020 | 1037 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 306 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 1745 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2007 | 432 | 0.060 |
Why?
|
| Protein Kinase C-alpha | 1 | 2004 | 24 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2004 | 37 | 0.060 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 64 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2004 | 97 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2004 | 175 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2004 | 308 | 0.060 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2003 | 37 | 0.050 |
Why?
|
| Cytokines | 1 | 2007 | 866 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 230 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2004 | 370 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2003 | 791 | 0.050 |
Why?
|
| Middle Aged | 4 | 2019 | 21119 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 31 | 0.050 |
Why?
|
| CpG Islands | 1 | 2021 | 51 | 0.050 |
Why?
|
| Aged | 3 | 2019 | 14842 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 103 | 0.050 |
Why?
|
| GTP-Binding Protein beta Subunits | 1 | 2000 | 8 | 0.050 |
Why?
|
| Neutrophil Infiltration | 1 | 2020 | 35 | 0.050 |
Why?
|
| GTP-Binding Protein gamma Subunits | 1 | 2000 | 11 | 0.050 |
Why?
|
| Receptors, Muscarinic | 1 | 2000 | 44 | 0.040 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2000 | 31 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2020 | 65 | 0.040 |
Why?
|
| Cartilage | 1 | 2020 | 51 | 0.040 |
Why?
|
| Arthritis, Experimental | 1 | 2020 | 38 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2020 | 88 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 43 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 93 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 2019 | 123 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2019 | 62 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 129 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 190 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2020 | 145 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2000 | 231 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 614 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 156 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 498 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 455 | 0.040 |
Why?
|
| NADPH Oxidase 4 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 61 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 56 | 0.040 |
Why?
|
| Macrophages | 1 | 2020 | 647 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 514 | 0.030 |
Why?
|
| Models, Biological | 1 | 2020 | 981 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 929 | 0.030 |
Why?
|
| United States | 1 | 2007 | 7338 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 499 | 0.030 |
Why?
|
| Culture Media | 1 | 2013 | 155 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 209 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2013 | 489 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2013 | 305 | 0.030 |
Why?
|
| Caveolin 1 | 1 | 2012 | 59 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2012 | 95 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 1593 | 0.030 |
Why?
|
| Hepatopulmonary Syndrome | 1 | 2011 | 10 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 179 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2011 | 58 | 0.020 |
Why?
|
| Vasodilation | 1 | 2011 | 85 | 0.020 |
Why?
|
| Bile Ducts | 1 | 2011 | 59 | 0.020 |
Why?
|
| Adult | 2 | 2019 | 21379 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2013 | 1663 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5710 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 1341 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8904 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2265 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2011 | 3703 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 2004 | 94 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2004 | 371 | 0.010 |
Why?
|
| beta-Adrenergic Receptor Kinases | 1 | 2000 | 7 | 0.010 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2000 | 10 | 0.010 |
Why?
|
| Serine | 1 | 2000 | 99 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2000 | 204 | 0.010 |
Why?
|
| Biological Transport | 1 | 2000 | 210 | 0.010 |
Why?
|
| Binding Sites | 1 | 2000 | 631 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 742 | 0.010 |
Why?
|